Norgine Releases H1 2018 Results
- Norgine generated sales of €196 million in the first half of 2018 (H1 2018), 28% higher than in H1 2017. This growth was driven by the established products added by the acquisition of Merus (+ €32 million sales) and growth of Norgine's key promoted products - particularly MOVICOL® and XIFAXAN® (+ €11million vs. H1 2017).
Norgine continues to drive performance of its products in Europe, Australia and New Zealand where it is investing for future growth.
Significant key business developments
Peter Stein, CEO at Norgine said: "Our performance during the first half of 2018 demonstrates that our strategy is working. We are continuing to bring transformative products to market for the benefit of patients. The established products acquired through Merus and our promoted products, in particular MOVICOL® and XIFAXAN®, are key growth drivers for us. With the addition of PLENVU® to our product portfolio, we anticipate further growth in the remainder of 2018 and into 2019. Our success is a reflection of the hard work of our "One Norgine" team which has built a strong platform through which we can attract new opportunities for the benefit of patients."
Media Contacts: Isabelle Jouin T: +44(0)1895-826237